These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 28142287)

  • 1. Overview and recent advances in the treatment of neuroblastoma.
    Whittle SB; Smith V; Doherty E; Zhao S; McCarty S; Zage PE
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):369-386. PubMed ID: 28142287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroblastoma: Therapeutic strategies for a clinical enigma.
    Modak S; Cheung NK
    Cancer Treat Rev; 2010 Jun; 36(4):307-17. PubMed ID: 20227189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-GD2 immunotherapy for neuroblastoma.
    Sait S; Modak S
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Therapies for Relapsed and Refractory Neuroblastoma.
    Zage PE
    Children (Basel); 2018 Oct; 5(11):. PubMed ID: 30384486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.
    Newman EA; Nuchtern JG
    Semin Pediatr Surg; 2016 Oct; 25(5):257-264. PubMed ID: 27955728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
    Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
    Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current management of neuroblastoma and future direction.
    Pastor ER; Mousa SA
    Crit Rev Oncol Hematol; 2019 Jun; 138():38-43. PubMed ID: 31092383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.
    Zage PE; Louis CU; Cohn SL
    Pediatr Blood Cancer; 2012 Jul; 58(7):1099-105. PubMed ID: 22378620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
    Owens C; Irwin M
    Crit Rev Clin Lab Sci; 2012; 49(3):85-115. PubMed ID: 22646747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
    London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
    Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.
    Liang WH; Federico SM; London WB; Naranjo A; Irwin MS; Volchenboum SL; Cohn SL
    JCO Clin Cancer Inform; 2020 Oct; 4():895-905. PubMed ID: 33058692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
    Défachelles AS; Cougnenc O; Carpentier P
    Bull Cancer; 2011 May; 98(5):559-69. PubMed ID: 21609890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
    Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
    Front Immunol; 2021; 12():690467. PubMed ID: 34367149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapeutic targets for neuroblastoma.
    Aravindan N; Herman T; Aravindan S
    Expert Opin Ther Targets; 2020 Sep; 24(9):899-914. PubMed ID: 33021426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State of the art in immunotherapy of neuroblastoma.
    Jabbari P; Hanaei S; Rezaei N
    Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methodological advances in the discovery of novel neuroblastoma therapeutics.
    Segura MF; Soriano A; Roma J; Piskareva O; Jiménez C; Boloix A; Fletcher JI; Haber M; Gray JC; Cerdá-Alberich L; Martínez de Las Heras B; Cañete A; Gallego S; Moreno L
    Expert Opin Drug Discov; 2022 Feb; 17(2):167-179. PubMed ID: 34807782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The quest to develop an effective therapy for neuroblastoma.
    Bhoopathi P; Mannangatti P; Emdad L; Das SK; Fisher PB
    J Cell Physiol; 2021 Nov; 236(11):7775-7791. PubMed ID: 33834508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in emerging drugs for the treatment of neuroblastoma.
    Berlanga P; Cañete A; Castel V
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):63-75. PubMed ID: 28253830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome.
    Cole KA; Maris JM
    Clin Cancer Res; 2012 May; 18(9):2423-8. PubMed ID: 22427348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.